---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015218"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:35:02.461704+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment

## Summary
- Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.
- Cash $51.3M as of March 31, 2026, down from $59.9M; company expects runway through 2027.
- ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required enrollment; interim analysis planned Q4 2026.
- Preeclampsia Phase 2 IST expansion cohort enrolling; updated dataset expected in Q2 2026.
- Rabbit study showed antibody response to DM199, preventing fetal development study; awaiting FDA response.

## SEC filing metadata
- accession: 0001437749-26-015218
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/0001437749-26-015218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/dmtp20260506_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015218
- JSON: https://secwatch.observer/filing/0001437749-26-015218.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015218.txt

## Source-grounded claims
- claim_id: 7353183e2989e92bf979c49341025dbb7e1cb959
  claim: DiaMedica Therapeutics Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ende.
  evidence_excerpt: Net loss was $10.0 million for the three months ended March 31, 2026, compared to $7.7 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/0001437749-26-015218-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.